Board of Directors  
Clinical and Scientific Advisory Board  
Historical Background  

Management Team

David Deperthes, Ph.D. – CEO and President
Founder and CEO of Med Discovery, Dr. Deperthes obtained his Ph.D. in Molecular and Cellular Biology from Laval University in Canada. Discoverer of a new prostate cancer marker, the kallikrein hK2, with Prof. Rolland R. Tremblay, he specialized in the development of new molecules for tumor targeting with J.P. Mach at the ISREC in Lausanne. Dr. Deperthes was Director of the Urology Research Unit at the University Hospital of Lausanne for 5 years. He won the NETS’ Prize in 2003 which consists of an intensive business and management training given at Babson College in Boston to a young entrepreneur selected by the NETS’ prize committee. Dr. Deperthes is also involved in different committees and associations such as Venturekick, Bioalps, or the Swiss Biotech Association.

Christoph Kündig, Ph.D. – Chief Scientific Officer
Dr. Kündig obtained his Ph.D. in life sciences at the Swiss Institute of Technology in Zurich, Switzerland. He joined Professor Marc Ouellette's laboratory at Laval University (Québec, Canada) in 1994 as post-doctoral fellow. He worked on drug target discovery and the molecular biology of Leishmaniosis. He then joined Essential Therapeutics Inc. Company in Mountain View, California as Senior Research Scientist. Med Discovery hired Dr. Kündig as R&D Director at the beginning of its R&D activity to head Med Discovery’s drug discovery, early preclinical and CMC operations. In 2010 Dr. Kündig was promoted CSO to manage the transition of its lead projects from preclinical into early clinical development.